Metalyse (tenecteplase) shortage collection
This content collection relates to the shortage in Australia that was resolved in October 2024
In August 2022, pharmaceutical company Boehringer Ingelheim advised us of a shortage of Metalyse (tenecteplase) injection - a medicine used to dissolve blood clots (thrombolysis) in the immediate period following a heart attack.
The shortage was due to manufacturing capacity constraints following increases in global demand. During the shortage, Australian health services carefully managed supply.
The shortage was resolved in October 2024.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.
Results for
"[search-keyword]"
Collection content
6 result(s) found, displaying 1 to 6
-
Medicine shortage alertsMetalyse is now available for use in all clinical settings.
-
Medicine shortage alertsMetalyse (tenecteplase) 40 mg for injection is to be discontinued; supply of Metalyse 50 mg for injection is not affected.
-
Medicine shortage alertsThe shortage of Metalyse (tenecteplase) is now resolved.
-
Medicine shortage alertsThe Metalyse (tenecteplase) shortage is now resolved.
-
Medicine shortage alertsThe shortage of Metalyse (tenecteplase) is now resolved.
-
Medicine shortage alertsRecommendations for clinicians to implement conservation methods no longer necessary as shortage is resolved.